Company
Universal Ibogaine, Inc.
Headquarters: Vancouver, BC, Canada
CEO: Mr. Nicholas Peter Karos
Universal Ibogaine, Inc. Categories
Canada Healthcare BiotechnologyCanada Healthcare Canada Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Universal Ibogaine Inc. provides treatment for addiction patients in Canada. It provides ibogaine addiction treatment to patients suffering from opioid addiction; and operates clinics that offer non-medical detox, inpatient and outpatient treatment, and aftercare recovery programs, as well as addiction intervention services. The company was incorporated in 2018 and is based in Vancouver, Canada.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Universal Ibogaine, Inc. has the following listings and related stock indices.
Stock: TSXV: IBO wb_incandescent